According to recent insights by DataM Intelligence, the blood cancer drugs market is projected to reach USD 75.4 billion by 2032, up from an estimated USD 38.9 billion in 2024. This surge is fueled by rising incidences of hematologic malignancies, greater accessibility to treatment in advanced economies, and consistent innovation by major pharmaceutical players.
The projected compound annual...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek